Outsmarting complex diseases with more intelligent medicines

Latest Press Release

Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at Upcoming Scientific Conferences

Senti Bio is a next-generation therapeutics company driven to create medicines that are programmable, controllable and designed to tackle even the most challenging diseases. Senti Bio has designed, built and tested thousands of sophisticated gene circuits that can be deployed into virtually any cell or gene therapy modality.

Senti Bio is applying its gene circuit technology platform to develop an internal pipeline of therapeutics that use allogeneic (CAR-NK) cells to address major challenges for people living with cancer.

The Senti gene circuit platform has the potential to usher in the next wave of medicine.

Building more control into everything we do

Design
Build
Test
Learn

By programming cells to sense their environment, perform computer-like logic and execute biologic functions, we are creating smarter therapies with enhanced functionality and greater control. Through the use of a rapid development process, which consists of design, build, test, learn and optimize, Senti Bio’s approach accelerates the engineering of gene circuits into therapeutic development candidates.

Advances in synthetic biology have enabled human biology to be programmed similarly to a computer, allowing us to envision gene circuit therapies that tackle diseases in completely new ways”

 

Tim Lu, CEO

Senti Bio

Engineering smarter therapies 
with gene circuit technology 

We are primarily focused on critical unmet needs in oncology. We are using allogeneic CAR-NK cells to demonstrate the benefit of gene circuits in difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma. Additionally, with potential partners, we plan to apply our gene circuit technology platform broadly to additional therapeutic areas, including neurology, immunology, cardiovascular disease, regenerative medicine and rare disease. 

 

Learn more

Our investors and partners

Our industry-leading partners share our vision of synthetic biology becoming an important pillar in next-generation cell and gene therapy.  

View partnering